Literature DB >> 7655742

Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3.

R Veerhuis1, P van der Valk, I Janssen, S S Zhan, W E Van Nostrand, P Eikelenboom.   

Abstract

In Alzheimer's disease (AD) patients, the complement components Clq, C4 and C3 can be detected in different types of beta/A4 plaques, one of the hallmarks of AD. Contradictory findings on the presence of late complement components in AD brains have been reported. Nevertheless, it was suggested in recent studies that in AD brain complement activation results in complement membrane attack complex (MAC) formation and that complement activation may act as an intermediate between beta/A4 deposits and the neurotoxicity observed in AD. In the present study the presence of a number of complement components and regulatory proteins in AD temporal cortex and, for comparison, in glomerulonephritis (GN) was analysed. In GN kidneys, besides Clq, Clr, Cls and C3, the late components and the C5b-9 complex are also associated with capillary basement membrane and mesangial immune complex deposits. In AD temporal cortex Clq, C4 and C3 are co-localized with beta/A4 deposits. However, in contrast to the GN kidney, the late complement components C5, C7 and C9, as well as the C5b-9 membrane attack complex cannot be detected in beta/A4 positive plaques. The absence of the cytolytic C5b-9 complex in AD brain suggests that in AD, the complement MAC does not function as the proposed inflammatory mediator between beta/A4 deposits and the neurofibrillary changes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655742     DOI: 10.1007/bf00192116

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

1.  Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.

Authors:  P A Kemp; J H Spragg; J C Brown; B P Morgan; C A Gunn; P W Taylor
Journal:  J Clin Lab Immunol       Date:  1992

2.  Complement C1qB and C4 mRNAs responses to lesioning in rat brain.

Authors:  G M Pasinetti; S A Johnson; I Rozovsky; M Lampert-Etchells; D G Morgan; M N Gordon; T E Morgan; D Willoughby; C E Finch
Journal:  Exp Neurol       Date:  1992-11       Impact factor: 5.330

Review 3.  Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease.

Authors:  P Eikelenboom; C E Hack; W Kamphorst; J M Rozemuller
Journal:  Res Immunol       Date:  1992 Jul-Aug

Review 4.  Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration.

Authors:  P C May; C E Finch
Journal:  Trends Neurosci       Date:  1992-10       Impact factor: 13.837

Review 5.  Clusterin: the intriguing guises of a widely expressed glycoprotein.

Authors:  D E Jenne; J Tschopp
Journal:  Trends Biochem Sci       Date:  1992-04       Impact factor: 13.807

6.  Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex.

Authors:  J Bariety; N Hinglais; S Bhakdi; C Mandet; M Rouchon; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

7.  Preparation and isolation of specific antibodies to complement components.

Authors:  S Bhakdi; M Muhly; M Roth
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

8.  A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

Review 9.  The immunopathology of Alzheimer's disease and some related disorders.

Authors:  R N Kalaria
Journal:  Brain Pathol       Date:  1993-10       Impact factor: 6.508

10.  Functional and structural similarities between protease nexin I and C1 inhibitor.

Authors:  W E Van Nostrand; L D McKay; J B Baker; D D Cunningham
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

View more
  20 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Authors:  F L Van Muiswinkel; P Eikelenboom
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 3.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

4.  Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.

Authors:  Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard R Kew
Journal:  Mol Immunol       Date:  2014-11-15       Impact factor: 4.407

5.  Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases.

Authors:  B D Chang; K Watanabe; E V Broude; J Fang; J C Poole; T V Kalinichenko; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

6.  Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Authors:  Sarah M Carpanini; Megan Torvell; Ryan J Bevan; Robert A J Byrne; Nikoleta Daskoulidou; Takashi Saito; Takaomi C Saido; Philip R Taylor; Timothy R Hughes; Wioleta M Zelek; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

7.  Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist.

Authors:  Diane L Sewell; Brendon Nacewicz; Frances Liu; Sinarack Macvilay; Anna Erdei; John D Lambris; Matyas Sandor; Zsuzsa Fabry
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

8.  Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner.

Authors:  C J Carter
Journal:  Int J Alzheimers Dis       Date:  2010-12-29

9.  The complement cascade in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Saffire H Krance; Che-Yuan Wu; Yi Zou; Huiyan Mao; Sina Toufighi; Xueyin He; Maureen Pakosh; Walter Swardfager
Journal:  Mol Psychiatry       Date:  2019-10-18       Impact factor: 15.992

10.  Using animal models to determine the significance of complement activation in Alzheimer's disease.

Authors:  David A Loeffler
Journal:  J Neuroinflammation       Date:  2004-10-12       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.